LIB Therapeutics

Executive Summary

LIB Therapeutics is a private, commercial-stage biopharmaceutical company developing lerodalcibep, a third-generation PCSK9 inhibitor for cardiovascular disease and familial hypercholesterolemia. Lerodalcibep is designed as a convenient, once-monthly subcutaneous injection to achieve LDL-C reduction. The company has completed Phase 3 trials and is preparing for regulatory submissions. Its focus on improving patient adherence and overcoming limitations of current lipid-lowering therapies positions it for potential approval. Despite being private, LIB Therapeutics represents a promising late-stage asset with a clear unmet need in cholesterol management.

Upcoming Catalysts (preview)

• Q2 2026FDA New Drug Application (NDA) submission for lerodalcibep85% success
• Q4 2026Phase 3 topline results from additional cardiovascular outcomes trial75% success
• Q3 2026European Medicines Agency (EMA) marketing authorization application80% success